Pricing Log in Create free account

argenex SE (ARGX) vs Royalty Pharma PLC (RPRX)

argenex SE and Royalty Pharma PLC are both Biotechnology companies. argenex SE is the larger, with a market value of $53.2B against $34.3B — 1.6× the size. argenex SE trades at the lower P/E: 29.6× against 42.3×. argenex SE grew revenue faster over the last twelve months: 70.6% against 10.0%. argenex SE has the higher net margin (32.2% vs 32.0%) and the higher return on invested capital (20.7% vs 5.28%). Across the 22 metrics below, argenex SE leads on 15 and Royalty Pharma PLC on 7.

Valuation

Metric ARGX RPRX Biotechnology median
P/E 29.55 42.27 8.50
P/S 9.58 10.76 9.71
P/B 6.06 2.79 2.13
Price to free cash flow 37.03 20.82 20.82
EV/EBITDA 29.63 22.88 0.64
EV/Sales 8.91 13.96 9.21
Earnings yield 3.38% 2.37% (33.15%)
Free cash flow yield 2.70% 4.80% (25.50%)

Profitability

Metric ARGX RPRX Biotechnology median
Gross margin 90.15% 100.00% 65.16%
Operating margin 30.06% 59.61% 0.00%
Net margin 32.20% 32.02% 0.00%
Free cash flow margin 25.87% 51.66% 0.00%
Return on equity 27.07% 8.42% (56.36%)
Return on assets 23.15% 4.26% (48.04%)
Return on invested capital 20.71% 5.28% 0.00%

Growth

Metric ARGX RPRX Biotechnology median
Revenue growth (TTM) 70.58% 10.01% 6.02%
EPS growth (last fiscal year) 53.13% (5.52%) 30.26%
Revenue growth, 5-year CAGR 130.77% 2.30% 9.41%
Net income growth, 5-year CAGR 0.00% (4.59%) 0.00%

Health

Metric ARGX RPRX Biotechnology median
Debt to equity 0.00 0.92 0.00
Current ratio 5.12 2.80 4.72
Net debt to EBITDA (3.23) 5.22 0.96

Dividend

Metric ARGX RPRX Biotechnology median
Dividend yield — 1.51% 0.09%
Payout ratio — 0.64 —

Size

Metric ARGX RPRX Biotechnology median
Market cap 53.22b 34.28b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack